Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Merck
Colorcon
Mallinckrodt
QuintilesIMS
Accenture
Julphar
Teva
Boehringer Ingelheim

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CADUET

« Back to Dashboard

Clinical Trials for Caduet

Trial ID Title Status Sponsor Phase Summary
NCT00150384 Clinical Utility of Caduet in Achieving Blood Pressure and Lipid Endpoints in a Specific Patient Population Completed Pfizer Phase 4 The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
NCT00332761 Caduet in an Untreated Subject Population Completed Pfizer Phase 4 The purpose of this study is to determine if Caduet will lower blood pressure to <140/90 mmHg and lower LDL Cholesterol to <100 mg/dL in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.
NCT00407537 Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors Completed Pfizer Phase 4 To investigate whether a Caduet based treatment strategy might result in greater reduction in total cardiovascular risk as compared to usual care in subjects with hypertension and additional risk factors.
NCT00412113 A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk Completed Pfizer Phase 4 The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia.
NCT00579254 Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors Terminated Pfizer Phase 4 To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the administration of the amlodipine/atorvastatin single pill to be appropriate
NCT01107743 Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) Completed Pfizer N/A In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin (Caduet® Combination Tablets) in daily medical practice will be examined. In addition, the necessity of special Investigation and post-marketing clinical studies will be examined, while investigating unexpected adverse drug reactions during the survey period and understanding of the status of frequency of adverse drug reactions in daily medical practice.
NCT01190007 Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients Completed Pfizer Phase 4 The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension and hypercholesterolemia, or with both angina pectoris and hypercholesterolemia.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Caduet

Condition Name

Condition Name for Caduet
Intervention Trials
Hypertension 6
Dyslipidemia 3
Hypercholesterolemia 3
Angina Pectoris 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Caduet
Intervention Trials
Hypercholesterolemia 3
Dyslipidemias 3
Hypertension 3
Angina Pectoris 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Caduet

Trials by Country

Trials by Country for Caduet
Location Trials
United States 66
Japan 8
Mexico 4
Korea, Republic of 3
Malaysia 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Caduet
Location Trials
Georgia 3
California 3
Virginia 3
Texas 3
Tennessee 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Caduet

Clinical Trial Phase

Clinical Trial Phase for Caduet
Clinical Trial Phase Trials
Phase 4 9
Phase 1 2
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Caduet
Clinical Trial Phase Trials
Completed 9
Terminated 1
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Caduet

Sponsor Name

Sponsor Name for Caduet
Sponsor Trials
Pfizer 8
Dr. Reddy's Laboratories Limited 2
Shanghai Institute of Hypertension 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Caduet
Sponsor Trials
Industry 10
Other 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Moodys
Covington
Teva
Colorcon
Boehringer Ingelheim
Baxter
Chinese Patent Office
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.